Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Immutep Ltd ( (AU:IMM) ) has provided an announcement.
Immutep has halted its Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small cell lung cancer after an Independent Data Monitoring Committee recommended discontinuation for futility based on an interim analysis of safety and efficacy. The company will stop enrolment and conduct an orderly wind-down of the global study, while reviewing the data to understand the outcome and reassess the program’s trajectory.
Despite the setback, Immutep plans to continue advancing its broader pipeline of LAG-3–based immunotherapies, including ongoing development of efti in other tumour types. Management now expects the termination of TACTI-004 to extend the company’s cash runway beyond its previous guidance and will update investors on capital allocation priorities once operational reviews and full data analyses are completed.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases, with a particular expertise in LAG-3 biology. Its lead candidate, eftilagimod alfa, is a first-in-class MHC Class II agonist designed to activate antigen-presenting cells and is being evaluated across multiple solid tumours, including NSCLC, HNSCC, soft tissue sarcoma and breast cancer.
Average Trading Volume: 3,345,886
Technical Sentiment Signal: Buy
Current Market Cap: A$582.1M
See more data about IMM stock on TipRanks’ Stock Analysis page.